The selective and potent anti-herpesvirus drug, (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU), has been examined for its inhibitory effects on several parameters of Epstein-Barr virus (EBV) infection in the lymphoblastoid cell lines Raji, P3HR-1, B-95-8 and P3 hybrid cells (a human embryo oropharyngeal cell line fused with a nasopharyngeal carcinoma cell line). At a dosage of 0.03 to 0.1 mM, BVdU caused a marked inhibition of (i) spontaneous viral capsid antigen (VCA) expression in B-95-8 and P3 hybrid cells, (ii) VCA expression and DNA synthesis in B-95-8 cells induced with croton oii and n-butyrate, (iii) early antigen (EA) expression and DNA synthesis in Raji cells superinfected with EBV, and (iv) VCA expression and DNA synthesis in B-95-8 cells superinfected with EBV. In its inhibitory effects on these various parameters of EBV infection, BVdU appears to be comparable to acyclovir [9-(2hydroxyethoxymethyl)guanine], another selective anti-herpesvirus drug which has been previously recognized as an effective inhibitor of EBV replication.
INTRODUCTION
BVdU [(E)-5-(2-bromovinyl)-2'-deoxyuridine] is a potent and selective anti-herpesvirus drug which is particularly effective against herpes simplex virus type 1 (HSV-1) (De Clercq et al., 1979) , varicella-zoster virus (VZV) (De Clercq et al., 1982) , pseudorabies virus (Reefschlfiger et al., 1982) , bovine herpesvirus type 1 (Weinmaster et al., 1982) , simian varicella virus (Soike et al., 1981) , herpesvirus saimiri (Honess et al., 1982) and nuclear polyhedrosis virus (Wang et al., 1983) . The selective anti-herpesvirus activity of BVdU depends on a specific phosphorylation by the virus-encoded 2'-deoxythymidine (dThd) kinase which converts the compound successively to its 5'-monophosphate and 5'-diphosphate (Cheng et al., 1981 ; Descamps & De Clercq, 1981 ; Fyfe, 1982) . Upon further phosphorylation to its 5'-triphosphate, BVdU may either prevent viral DNA synthesis (Allaudeen et al., 1981) or be incorporated into viral DNA (Allaudeen et al., 1982a) . The incorporation of BVdU into DNA may hamper its template activity during replication and transcription (Sagi et al., 1981) and/or facilitate its degradation (Mancini et al., 1983) .
Whether BVdU also inhibits Epstein-Barr virus (EBV), another virus belonging to the herpesvirus family, has not yet been reported. EBV can be considered as a prime human tumour virus candidate. It is associated with Burkitt's lymphoma and nasopharyngeal carcinoma, and cell lines derived from such turnout sources carry EBV DNA sequences. Some of the lymphoblastoid cell lines derived from Burkitt's tymphoma, e.g. P3HR-1, produce infectious virus particles spontaneously; these cells also express other viral products such as early antigens (EA) and viral capsid antigens (VCA). Other lymphoblastoid cell lines, e.g. Raji, express EBVspecific nuclear antigen (EBNA) but do not produce other viral products, EA, VCA or intact virions. They will only do so after superinfection with EBV (derived from a virus-producing cell 'f Present address: Smith Kline and French Laboratories, Philadelphia, Pa. 19101, U.S.A. 0022-1317/84/0000-5722 $02.0001984 SGM z.-x. ZHANG AND OTHERS line such as P3HR-1). Like P3HR-1, B-95-8 are also virus-producing cells, originally derived from a marmoset lymphocyte cell line infected with EBV. The present studies were designed to determine the effects of BVdU on the replicative cycle of EBV in (i) productively infected cells, e.g. P3HR-1, B-95-8 and P3 hybrid cells (for the origin of the P3 hybrid cell line, see below) and (ii) latently infected cells, e.g. Raji, after superinfection with EBV (derived from P3HR-1 cells). As parameters of the EBV infection we measured VCA and EA expression as well as DNA synthesis (following superinfection). The inhibitory effects of BVdU on EBV replication were directly compared with those of ACV [acyclovir, 9-(2hydroxyethoxymethyl) guanine] and, in some instances, also Ara-T (1-fl-D-arabinofuranosylthymine), two other compounds which have previously been shown to inhibit EBV replication (Colby et at., 1980; Ooka & Calender, 1980; Lin et al., 198l ; Altaudeen et al., 1982b) .
METHODS
Cell lines. Raji cells (Epstein et al., 1966) and P3HR-1 cells (Hinuma & Grace, 1967) are two human lymphoblastoid cell lines derived from Burkitt's lymphoma. The B-95-8 cell line (Miller & Lipman, 1973) is a marmoset lymphocyte cell line originally infected with EBV (from a human cell line established from a patient with acute infectious mononucleosis). P3 hybrid cells were obtained by fusion of a nasopharyngeal carcinoma (NPC) cell line with a human embryo oropharyngeal cell line; these P3 hybrid cells were established at the Institute of Oncology, Chinese Academy of Medical Sciences, Beijing (Y.-X. Liu & W.-P. Dong, unpublished data) . The P3 hybrid cell line shows spontaneous VCA expression in 20 to 30~ of the cells.
The cells were maintained at 2 × l0 s to l06 cells/ml at 37 °C and 5~o CO2 in 50 ml or 250 ml glass prescription bottles. The growth medium consisted of RPMI 1640 medium supplemented with 20~ newborn calf serum, 100 units/ml penicillin, 100 gg/ml streptomycin, 100 ~tg/ml kanamycin and 1 to 2 gg/ml nystatin (pH ranging from 6.8 to 7.2). In separate experiments it was ascertained that the antiviral activity of BVdU (as assessed with HSV-1) was not affected by the presence of 20~ newborn calf serum in the cell culture medium.
Drugs. BVdU was synthesized by R. Busson and H. Vanderhaeghe at the Rega Institute for Medical Research, Leuven, essentially as described by Jones et al. (1979) . Acyclovir was obtained from Burroughs Wellcome Co., Research Triangle Park, N.C., U.S.A. (courtesy of Dr G. B. Elion) and Ara-T was obtained from Yamasa Shoyu Company Ltd., Choshi, Japan (courtesy of Dr H. Machida). The compounds were dissolved at a concentration of 2 mg/mI in RPMI I640, pH 7-0 and stored at 4 °C.
Chemical inducers. Croton oil and n-butyrate were used as inducers of VCA expression. Croton oil was obtained from the Institute of Materia Medica in Beijing, dissolved in ethanol and stored at 4 °C. Sodium n-butyrate was dissolved in RPMI 1640 and also kept at 4 °C. VCA expression was induced by culturing the cells in the presence of 500 ng/ml croton oil and 4 mM-n-butyrate.
Radiochemicals. [Me -3 H]2'-Deoxythymidine ([Me-3H]dThd) was obtained from the Institute of Atomic Energy, Chinese Academy of Sciences, Beijing. The compound had a specific radioactivity of 35 mCi/mmol. Antisera. Sera positive for both EBV EA and VCA (EA+/VCA + sera) and sera positive for VCA but negative for EA (EA-/VCA ÷ sera) were obtained from NPC patients at the Oncology Hospital, Chinese Academy of Medical Sciences, Beijing. The sera were tested on Raji cell smears (for EA antibody) or B-95-8 cell smears (for VCA antibody). For detection of EA and VCA the sera were used at a fourfold higher concentration than the endpoint antibody titre.
Immunoenzymic assay. Indirect immunoenzymic assays for EA and VCA detection were performed as described previously (Nakane & Kawaoi, 1974; Liu et al., 1979) . The cell monolayers were dried and fixed in acetone for 30 min, rehydrated in phosphate-buffered saline (PBS, pH 7.6), dried again, and then treated with EA +/VCA + or EA /VCA + serum at 37 °C for 30 min. After the cell smears had been submitted to three successive treatments with PBS for a 5 min period each, they were exposed to anti-human IgA horse IgG (for EA detection) or antihuman IgG horse IgG (for VCA detection); this horse IgG had been previously conjugated with peroxidase. The cells were then washed three times with PBS, and the number of VCA-or EA-positive cells was enumerated after application of Tris HC1 buffer (pH 7-6) containing 3',3'-diaminodiphenylenediamine and 0-1 ~o H2Oz.
Preparation of EBV stock. P3HR-I or B-95-8 cells were incubated for 3 to 4 days in the presence of 500 ng/ml croton oil and 4 mM-n-butyrate, and then further incubated for another 8 to 10 days in the absence of the inducers. The cells were pelleted by centrifugation at 3000 rev/min for 30 min; the supernatant was collected and from this supernatant the virus was precipitated by centrifugation at 43 000 g for 90 min (Henle et al., 1970) . The precipitate was then suspended in 2 to 3 ml and served as the EBV stock. It was used at a dilution that gave EA expression in 30~ of the cells.
Determination of DNA synthesis in superinfected cells. Raji or B-95-8 cells were superinfected with EBV, essentially as described previously (Henle et al., 1970; Yajima et al., 1976; Shaw et al., 1977) . The cells were seeded into glass tubes at a concentration of 2 x 105 cells/tube, infected with EBV (stock diluted 10 t) for 30 min, and incubated in the presence of the indicated drug (BVdU or ACV) concentrations for 40 h (unless stated otherwise). [Me -3 H]dThd was added at 1 ~tCi per 2 × 105 cells during the last 20 h of this incubation period. At the end of the incubation period, the cells were transferred to glass fibre filters, washed twice with cold trichloroacetic acid (10~) and twice with cold ethanol. The filters were then dried at 50 °C and assayed for radioactivity in a scintillation counter.
RESULTS
Growth ofB-95-8 cells B-95-8 cells were suspended at 2 x 105 per ml and cultured in the presence of various concentrations of BVdU (Fig. 1) . Cell densities increased linearly for a period of 7 days. From the 7th day, no further increase in cell population was noted. Within the range of concentrations tested (0.1 to 1 mM), BVdU caused a dose-dependent inhibition of cell growth. At 0-1 mM, BVdU caused a 10 to 20 Yo reduction of the final cell number (see also Fig. 2 ). This BVdU concentration was routinely used in all further experiments.
Expression of I/CA in chemically induced B-95-8 cells
At a concentration (0.1 mrs) which had little influence on the growth rate of the cells (at an average 15 Yo reduction in cell number), BVdU markedly suppressed the expression of VCA in B-95-8 cells induced by croton oil and n-butyrate (about 70~ reduction of VCA expression). Upon exposure to these chemicals up to 50~ of the B-95-8 cells became VCA ÷ (Fig. 2 ). In the presence of 0.1 mM-BVdU, the percentage of VCA + cells was reduced to 15 ~. This suppressive effect remained apparent during the whole period of incubation of the cells with the chemical inducers. When the latter were removed, the number of VCA-positive cells declined rapidly. However, the inhibitory effect of BVdU on VCA expression persisted even after the drug had been removed (Fig. 2) .
Additional experiments were designed to determine the minimum inhibitory concentration of BVdU required to reduce VCA expression by 50~. This concentration appeared to be 0.01 mM. At 0.003 mM, BVdU did not markedly inhibit VCA expression in chemically induced B-95-8 cells. |  I  I  I  I  I  I  I  i  I  I  oi  I  I  I  I   x   ?   t  I  T  I  I  T  I  1  t  1  I  I  I  I  I  1   0  2  4  6  8  10  12  14  16 Time ( The cells were incubated for 7 days in the presence of croton oil (500 ng/ml) and n-butyrate (4 mM) in the absence (&) or presence of 0.1 mM-BVdU (A). After 2 and 4 days the cells were collected and resuspended in the same volume of fresh growth medium plus croton oil and n-butyrate and with or without BVdU. At the 7th day (as indicated by the arrow), the medium was replaced by fresh growth medium without BVdU and inducers (croton oil, n-butyrate). The cell growth rate ( ) was monitored under the same conditions as VCA expression (--), thus in the absence of BVdU (O) and presence of 0.1 mM-BVdU (©). 
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Spontaneous expression of VCA in B-95-8 cells
Under normal circumstances, i.e. in the absence of any chemical inducer, VCA expression occurred spontaneously in about 3 to 5% of the B-95-8 cells (Fig. 3) . In the presence of 0-1 or 0.3 mM-BVdU the percentage of cells expressing VCA was reduced to less than 1%. Upon removal of BVdU (at the 7th day), the number of VCA-positive cells gradually increased to attain approximately 2.5% by the 15th day. Thus, as noted for VCA expression in chemically induced B-95-8 cells, spontaneous VCA expression continued to be reduced for at least 1 week after removal of BVdU from the cell culture medium.
Spontaneous expression of VCA in P3 hybrid cells
P3 hybrid cells showed a much higher rate of spontaneous VCA expression than B-95-8 cells: up to 30% of the P3 hybrid cells expressed VCA in the absence of any inducer (Fig. 4b ). When exposed to 0.1 mM-BVdU, only 10% of the P3 hybrid cells remained VCA-positive. Similarly, two other nucleoside analogues, ACV and Ara-T, which have been previously recognized as effective inhibitors of EBV replication (Colby et al., 1980; Ooka & Calender, 1980) , reduced the number of VCA-positive P3 hybrid cells to about 10% when assayed at the same concentration (0.1 mM) as BVdU. With all three compounds, the reduction of VCA expression became apparent after 1 day of incubation. At the concentrations used (0.1 mM), BVdU, ACV and Ara-T had little effect on the cell growth rate (at the most 20 % reduction in the final cell numbers) (Fig.  4a ). z.-x. ZHANG AND OTHERS 
VCA expression and DNA synthesis in chemically induced B-95-8 cells
Concomitantly with its inhibitory effect on VCA expression (Fig. 2) , BVdU also inhibited DNA synthesis in B-95-8 cells induced by croton oil and n-butyrate (Table 1) . This inhibition was observed with both 0.03 raM-and 0.1 mM-BVdU. Like BVdU, ACV also reduced VCA expression and DNA synthesis in chemically induced B-95-8 cells.
VCA expression and DNA synthesis in B-95-8 cells superinfected with EBV
EBV-superinfected B-95-8 cells, like chemically induced B-95-8 cells, responded to BVdU treatment with a marked reduction in both VCA expression and DNA synthesis (Table 2) . Again, this inhibition was observed with both 0.03 raM-and 0.1 mM-BVdU. A similar inhibitory effect on VCA expression was observed with ACV. However, at the concentrations tested (0-03 and 0-1 mM), ACV did not markedly affect DNA synthesis in EBV-superinfected B-95-8 cells.
DNA synthesis in Raft cells superinfected with EBV
BVdU and ACV were then compared for their inhibitory effects on EBV replication in superinfected Raji cells. Both compounds were about equally effective in suppressing DNA synthesis in EBV-superinfected Raji cells (Fig. 5 ). They effected a 50~ inhibition of DNA synthesis at a concentration of approximately 0-1 mM. In the experiments presented in Fig. 5 , DNA synthesis was measured at 40 h after superinfection with EBV. In another set of experiments, DNA synthesis was monitored at various times (ranging from 2 to 6 days) postinfection (Fig. 6 ). [Me-3H]dThd was invariably added during the last 20 h of the whole incubation period. Irrespective of the time after infection at which DNA synthesis was determined, BVdU (at 0.1 raM) reduced it by approx. 50~.
EA expression and DNA synthesis in Raft cells superinfected with EBV
When assayed under optimal conditions, i.e. at a concentration of 0.1 mM (see Fig. 5 ) and at 40 h after superinfection (see Fig. 6 ), both BVdU and ACV brought about a significant reduction in EA expression, concomitantly with their inhibitory action on DNA synthesis IP: 54.70.40.11 Table 3) . Combination of ACV and BVdU achieved a greater inhibition of EA expression and DNA synthesis than did either drug alone.
Effect of BVdU on EBV infection
Release of retrovirus particles from P3HR-1 cells
The possibility that BVdU might stimulate the release of endogenous retrovirus particles was examined with P3HR-1 cells. The cells were grown in the presence of 0.3 mM-BVdU for a period of either 6 days or 8 weeks. In neither case was reverse transcriptase activity detected in the cell culture medium or cell extracts, suggesting that under these conditions BVdU failed to trigger the release of retrovirus particles (data not shown).
DISCUSSION
Few substances have been reported to inhibit EBV replication: these include phosphonoacetate (PAA), phosphonoformate (PFA), ACV and Ara-T. PAA has been shown to inhibit EBV DNA synthesis and VCA expression in productively infected lymphoblastoid cells, such as B-95-8 cells (Summers & Klein, 1976) . PAA also inhibits transformation of normal human peripheral lymphocytes by EBV (Thorley-Lawson & Strominger, 1976) . Similar effects have been attributed to PFA (Margalith et al., 1980; Datta & Hood, 1981) . More recently, ACV and Ara-T were shown to inhibit EBV DNA synthesis and VCA expression in EBV-superinfected Raji cells (Colby et al., 1980) or chemically induced P3HR-1 cells (Ooka & Calender, 1980) . The present report extends this observation to another potent anti-herpesvirus compound, namely BVdU.
BVdU was found to suppress several manifestations of EBV infection: EA expression, VCA expression and DNA synthesis. These parameters of EBV infections were monitored in a number of cell lines, such as Raji, P3HR-1, B-95-8 and P3 hybrid cells, which were either not stimulated or were chemically induced or superinfected with EBV. The minimum concentration at which BVdU inhibited EBV infection (as based on a 50~ reduction of VCA expression in B-95-8 cells induced by croton oil and n-butyrate) was 0-01 mM. This compares favourably with the concentration (approx. 0-5 mi) at which PAA and PFA were found to be inhibitory towards EBV replication.
In several tests we included ACV as the reference compound. BVdU and ACV proved equally effective in suppressing spontaneous VCA expression in P3 hybrid cells (Fig. 4) and DNA synthesis in EBV-superinfected Raji cells (Fig. 5) . Ara-T inhibited spontaneous VCA expression in P3 hybrid cells to the same extent as BVdU and ACV. Within the concentration range of 0-03 to 0-! triM, BVdU appeared more effective than ACV in inhibiting VCA expression and DN A synthesis in chemically induced or superinfected B-95-8 cells (Tables 1 and  2) . However, these observations should be extended to a wider range of drug concentrations before the relative potencies of BVdU and ACV as inhibitors of EBV replication can be fully assessed. In previous studies Colby et al. (1981) noted that for ACV the dose required for 50~ inhibition of EBV DNA synthesis in superinfected Raji cells was 7 ~tM. This seems to be much lower than the 50~ inhibitory dose of ACV for DNA synthesis in EBV-superinfected B-95-8 cells ( Table 2) .
Although BVdU, like ACV and Ara-T, can be considered as an effective inhibitor of EBV replication, it should be emphasized that its inhibitory effects against EBV replication are achieved at a concentration (0.01 mM or 3"3 btg/ml) which is much higher than its minimal inhibitory concentration (0-01 vg/ml) for other herpesviruses such as HSV-1 and VZV (De Clercq et al., 1979 , 1982 . This difference in efficiency should be taken into account when extrapolating from the current laboratory findings to potential clinical usefulness.
The mechanism of action of BVdU against EBV replication remains to be elucidated. Two important aspects in the selective inhibition of HSV-1 and VZV replication by BVdU are (i) a specific phosphorylation by the virus-encoded dThd kinase (Cheng et al., 1981 ; Descamps & De Clercq, 1981) and (ii) a specific inhibitory effect of BVdU 5'-triphosphate on the viral DNA polymerase (Allaudeen et al., 1981) . It is unlikely that either of these two enzymes would play an important part in the inhibition of EBV infection by BVdU, since (i) EBV is not assumed to encode a specific dThd kinase and (ii) EBV DNA polymerase is poorly sensitive to inhibition by BVdU triphosphate (Allaudeen et al., 1981) .
In its activity against EBV, BVdU may follow the same mechanism of action as ACV. ACV is phosphorytated to the triphosphate to a greater extent in EBV-infected lymphoblastoid cell lines than in uninfected cell lines (Colby et al., 1981) . In its triphosphate form, ACV would then interfere with EBV DNA synthesis. However, EBV DNA polymerase does not appear to be the primary target for the inhibition of EBV replication by ACV (Allaudeen et al., 1982b) . On the contrary, ACV may be incorporated into DNA and its inhibitory action on EBV could be subsequent to this incorporation. BVdU may act in a similar fashion. Upon conversion of BVdU to BVdU 5'-triphosphate in the EBV-infected cell (by enzymes which have not yet been identified), BVdUTP may, as has been shown previously for HSV-l-infected cells (Allaudeen et al., 1982 a; Mancini et al., 1983) , be incorporated into viral DNA, and thereby disturb its normal functioning.
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